U.S. Drug Patent Complexities Pose Challenges to Generic Market Entry, USPTO Report Reveals

By Dani Kass (June 12, 2024, 10:55 PM EDT) — The complexity of the U.S. drug patent landscape continues to challenge efforts to streamline the entry of generic drugs into the market. A recent report from the U.S. Patent and Trademark Office reveals that the timing and manner in which generics become available can vary significantly among different drugs. This variation is not necessarily correlated with the number of patents each drug holds. This analysis was requested by a senior member of the U.S. Senate’s Intellectual Property Subcommittee, shedding light on the intricate nature of pharmaceutical patenting and its regulatory environment. For further details, read the full article on Law360.